Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells $261,831.32 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,388 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $27.89, for a total transaction of $261,831.32. Following the transaction, the chief financial officer owned 264,117 shares in the company, valued at approximately $7,366,223.13. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.09, for a total transaction of $1,943,389.47.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total transaction of $619,243.91.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $1.19 during midday trading on Tuesday, reaching $27.43. The company’s stock had a trading volume of 7,895,463 shares, compared to its average volume of 26,328,367. The stock has a market capitalization of $6.40 billion, a P/E ratio of -43.53 and a beta of 2.40. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a 50 day moving average price of $32.14 and a 200-day moving average price of $26.05. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue was up 38.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.17 earnings per share. As a group, equities analysts predict that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Binnacle Investments Inc bought a new position in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Versant Capital Management Inc raised its stake in shares of Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares in the last quarter. Silicon Valley Capital Partners purchased a new stake in Hims & Hers Health during the 3rd quarter worth about $48,000. Finally, Bogart Wealth LLC boosted its stake in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HIMS has been the subject of several research analyst reports. JPMorgan Chase & Co. decreased their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Morgan Stanley lifted their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Truist Financial increased their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Citigroup decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.